Sevabertinib, targeting HER2 and EGFR mutations, received FDA breakthrough designation for HER2+ NSCLC, showing a 59% overall ...
An oncology pharmacist shares how a treatment takes a different approach to treating chronic graft-versus-host disease (GVHD) ...
The top news to come out of skin cancer coverage this year for MHE focused on blood or marrow transplant recipients ...
Leyla O. Shune, MD, discusses an expanded access program in the United States that administered axatilimab to patients with ...
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback